-
Something wrong with this record ?
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry
P. Potuznik, J. Drahota, D. Horakova, M. Peterka, A. Mazouchova, D. Matyas, Z. Pavelek, M. Vachova, E. Recmanova, I. Stetkarova, J. Libertinova, J. Mares, P. Stourac, M. Grunermelova, A. Martinkova, J. Adamkova, P. Hradilek, R. Ampapa, M. Dufek,...
Status not-indexed Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
BACKGROUND: Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). OBJECTIVES: Provide experience with cladribine therapy in a real-world setting. METHODS: This is a registry-based retrospective observational cohort study. First, using data from the Czech nationwide registry ReMuS, we analysed patients who initiated cladribine from September 1, 2018 to December 31, 2021. Second, we analysed a subgroup of patients who initiated cladribine between September 1, 2018 to June 30, 2020, thus possessing a follow-up period of at least 2 years. We evaluated demographic and MS characteristics including disease-modifying therapies (DMTs) before and after cladribine administration, relapses, Expanded Disability Status Scale (EDSS), and adherence. RESULTS: In total, 617 patients (335 with follow-up of at least 2 years) started cladribine therapy in the study period (mean age 37.0, mean disease duration 8.4 years, 74.1% females). In most cases, cladribine was administered as a second-line drug, a total of 80.7% had been escalated from a platform DMT. During 2 years before cladribine initiation, the average annualised relapse rate (ARR) was .67. Following cladribine initiation, the ARR decreased to .28 in the first year and .22 in the second year. Overall, across the entire two-year treatment period, 69.0% of patients were relapse-free and the average ARR was .25. As for EDSS development, the median baseline EDSS was 2.5 and remained stable even after 24 months. The adherence to treatment ranged of around 90%. CONCLUSION: This nationwide study confirms the efficacy of cladribine in real-world settings, especially in patients who are not treatment-naïve. In addition, the study shows an exceptionally high adherence rate, a finding that underscores the invaluable role of cladribine, but also the value of registry-based studies in capturing real-world clinical practice.
Department of Economic Statistics Prague University of Economics and Business Prague Czech Republic
Department of Neurology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Neurology Hospital of Jihlava Jihlava Czech Republic
Department of Neurology Hospital Pardubice Pardubice Czech Republic
Department of Neurology KZ a s Hospital Teplice Teplice Czech Republic
Department of Neurology Thomayer Hospital Prague Czech Republic
Department of Neurology Tomas Bata Hospital Zlin Czech Republic
Department of Neurology University Hospital and Masaryk University Brno Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018174
- 003
- CZ-PrNML
- 005
- 20241016082017.0
- 007
- ta
- 008
- 241008e20240724xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/11795735241262743 $2 doi
- 035 __
- $a (PubMed)39055049
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Potuznik, Pavel $u Department of Neurology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Plzen, Czech Republic $1 https://orcid.org/0000000182417798
- 245 10
- $a Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry / $c P. Potuznik, J. Drahota, D. Horakova, M. Peterka, A. Mazouchova, D. Matyas, Z. Pavelek, M. Vachova, E. Recmanova, I. Stetkarova, J. Libertinova, J. Mares, P. Stourac, M. Grunermelova, A. Martinkova, J. Adamkova, P. Hradilek, R. Ampapa, M. Dufek, E. Kubala Havrdova, D. Stastna
- 520 9_
- $a BACKGROUND: Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). OBJECTIVES: Provide experience with cladribine therapy in a real-world setting. METHODS: This is a registry-based retrospective observational cohort study. First, using data from the Czech nationwide registry ReMuS, we analysed patients who initiated cladribine from September 1, 2018 to December 31, 2021. Second, we analysed a subgroup of patients who initiated cladribine between September 1, 2018 to June 30, 2020, thus possessing a follow-up period of at least 2 years. We evaluated demographic and MS characteristics including disease-modifying therapies (DMTs) before and after cladribine administration, relapses, Expanded Disability Status Scale (EDSS), and adherence. RESULTS: In total, 617 patients (335 with follow-up of at least 2 years) started cladribine therapy in the study period (mean age 37.0, mean disease duration 8.4 years, 74.1% females). In most cases, cladribine was administered as a second-line drug, a total of 80.7% had been escalated from a platform DMT. During 2 years before cladribine initiation, the average annualised relapse rate (ARR) was .67. Following cladribine initiation, the ARR decreased to .28 in the first year and .22 in the second year. Overall, across the entire two-year treatment period, 69.0% of patients were relapse-free and the average ARR was .25. As for EDSS development, the median baseline EDSS was 2.5 and remained stable even after 24 months. The adherence to treatment ranged of around 90%. CONCLUSION: This nationwide study confirms the efficacy of cladribine in real-world settings, especially in patients who are not treatment-naïve. In addition, the study shows an exceptionally high adherence rate, a finding that underscores the invaluable role of cladribine, but also the value of registry-based studies in capturing real-world clinical practice.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Drahota, Jiri $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u Endowment Fund IMPULS, Prague, Czech Republic $1 https://orcid.org/0000000334162094
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Plzen, Czech Republic $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000205884592
- 700 1_
- $a Mazouchova, Aneta $u Endowment Fund IMPULS, Prague, Czech Republic $u Department of Economic Statistics, Prague University of Economics and Business, Prague, Czech Republic
- 700 1_
- $a Matyas, David $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, Prague, Czech Republic
- 700 1_
- $a Pavelek, Zbysek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000217728781
- 700 1_
- $a Vachova, Marta $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u Department of Neurology, KZ a.s., Hospital Teplice, Teplice, Czech Republic $1 https://orcid.org/000000028158724X
- 700 1_
- $a Recmanova, Eva $u Department of Neurology, Tomas Bata Hospital, Zlin, Czech Republic
- 700 1_
- $a Stetkarova, Ivana $u Department of Neurology, 3rd Faculty of Medicine, Charles University in Prague and Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Libertinova, Jana $u Department of Neurology, Second Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Mares, Jan $u Department of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Stourac, Pavel $u Department of Neurology, University Hospital and Masaryk University Brno, Brno, Czech Republic
- 700 1_
- $a Grunermelova, Marketa $u Department of Neurology, Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Martinkova, Alena $u Department of Neurology, Hospital Pardubice, Pardubice, Czech Republic
- 700 1_
- $a Adamkova, Jana $u Department of Neurology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
- 700 1_
- $a Hradilek, Pavel $u Department of Neurology, University Hospital Ostrava and Medical Faculty, Ostrava University, Ostrava, Czech Republic
- 700 1_
- $a Ampapa, Radek $u Department of Neurology, Hospital of Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Dufek, Michal $u 1st Department of Neurology, University Hospital U Svate Anny and Masaryk University Brno, Brno, Czech Republic
- 700 1_
- $a Kubala Havrdova, Eva $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Stastna, Dominika $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000324184847
- 773 0_
- $w MED00215617 $t Journal of central nervous system disease $x 1179-5735 $g Roč. 16 (20240724), s. 11795735241262743
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39055049 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016082012 $b ABA008
- 999 __
- $a ok $b bmc $g 2196485 $s 1230125
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 16 $c - $d 11795735241262743 $e 20240724 $i 1179-5735 $m Journal of central nervous system disease $n J Cent Nerv Syst Dis $x MED00215617
- LZP __
- $a Pubmed-20241008
